Raymond Prudo-Chlebosz - Dec 2, 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Dec 2, 2024
Transactions value $
$1,006,286
Form type
4
Date filed
12/3/2024, 05:48 PM
Previous filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX Ordinary Shares, par value $0.0001 per share Award $503K +419M +11.46% $0.00 4.08B Dec 2, 2024 Direct F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 38.7M Dec 2, 2024 Praxis Trustees Limited F1
holding AKTX Ordinary Shares, par value $0.0001 per share 801M Dec 2, 2024 RPC Pharma Limited F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Warrants (Right to Buy) Award $503K +419M $0.00 419M Dec 2, 2024 Ordinary Shares, par value $0.0001 per share 419M $0.00 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant.
F3 The warrants have an exercise price of $0.001130 per Ordinary Share.